San Diego-based Sorrento Therapeutics said Thursday that it has acquired Sherrington Pharmaceuticals, a company developing chronic pain treatments for end-stage cancer patients and other severe pain indications. Financial terms of the buy were not disclosed. Sorrento Therapeutics said that Sherrington's lead candidate is a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor.
Top NewsFriday, October 11, 2013
Sorrento Therapeutics Buys Sherrington Pharmaceuticals